USTEKINUMAB (STELARA) INJECTION INDUCTION & Maintenance for Psoriasis - Adult, Outpatient, Infusion Center

Defaults for orders not otherwise specified below:
- **Interval:** INDUCTION – Every 28 days x 2 treatments
- **Interval:** MAINTENANCE – Every 84 days (starting day 112 after induction)

**Duration:**
- Until date: __________
- 1 year
- _____ # of Treatments

**Anticipated Infusion Date** ____________  ICD 10 Code with Description _______________________

**Height** ____________ (cm)  **Weight** ____________ (kg)  **Allergies** __________________________________

**Provider Specialty**
- ☐ Allergy/Immunology
- ☐ Cardiology
- ☐ Gastroenterology
- ☐ Genetics
- ☐ Infectious Disease
- ☐ Internal Med/Family Practice
- ☐ Nephrology
- ☐ Neurology
- ☐ OB/GYN
- ☐ Other
- ☐ Otolaryngology
- ☐ Pulmonary
- ☐ Rheumatology
- ☐ Surgery
- ☐ Urology

**Site of Service**
- ☐ SH Gerber
- ☐ SH Lemmen Holton (GR)
- ☐ SH Pennock
- ☐ SH United Memorial
- ☐ SH Helen DeVos (GR)
- ☐ SH Ludington
- ☐ SH Reed City
- ☐ SH Zeeland

**Appointment Requests**
- ☑ Infusion Appointment Request
  
  **Status:** Future, **Expected:** S, **Expires:** S+365, **Sched. Tolerance:** Schedule appointment at most 3 days before or at most 3 days after, Infusion and possible labs. Verify that all INDUCTION/LOADING DOSES have been scheduled and offset appropriately when scheduling MAINTENANCE DOSES.

**Provider Ordering Guidelines**
- ☑ ONC PROVIDER REMINDER 15
  
  **USTEKINUMAB (STELARA) Plaque psoriasis:** SubQ:

  Tuberculosis surveillance and management: Screen prior to starting therapy. Treat latent infection prior to starting therapy.

  Initial and maintenance: Note: Following an interruption in therapy, re-treatment may be initiated at the initial dosing interval.

  Less than or equal to 100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter

  Greater than 100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter. Note: Doses of 45 mg given to patients >100 kg were also efficacious; however, 90 mg is the recommended dose in these patients due to greater efficacy.

  Psoriatic arthritis: SubQ: Note: When used for psoriatic arthritis, may be administered alone or in combination with methotrexate.

  Initial and maintenance: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

  Coexistent psoriatic arthritis and moderate to severe plaque psoriasis in patients greater than 100 kg: Initial and maintenance: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

**Safety Parameters and Special Instructions**
- ☑ ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 6
  
  Verify all INDUCTION/LOADING DOSES given prior to start of MAINTENANCE DOSES

**CONTINUED ON PAGE 2 ➔**

**NOTE:** Epic Treatment/Therapy Plan Orders. To be scanned/attached to the appropriate Infusion Referral Order in Epic.
Safety Parameters and Special Instructions (continued)

☑ ONC SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS 5
TUBERCULOSIS SURVEILLANCE AND MANAGEMENT RECOMMENDATIONS: Screen prior to treatment. Treat latent infection prior to starting therapy.

Labs

<table>
<thead>
<tr>
<th>Lab Description</th>
<th>Interval</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑ Arrange For Patient To Have Id Tb Skin Test Administered And Read Or Serum Tb Screening Lab Prior To Therapy Or Annually</td>
<td></td>
<td></td>
</tr>
<tr>
<td>☐ ONC PROVIDER REMINDER 28</td>
<td>Once</td>
<td>1 treatment</td>
</tr>
<tr>
<td></td>
<td>Arrange for patient to have intradermal TB skin test (tuberculin PPD) screening performed and read prior to initiating therapy and annually.</td>
<td></td>
</tr>
<tr>
<td>☐ TB Screen (Quantiferon Gold)</td>
<td>Once</td>
<td>1 treatment</td>
</tr>
<tr>
<td>☐ Labs: ___________________________</td>
<td>Every ___ days</td>
<td>Until date: _______</td>
</tr>
<tr>
<td></td>
<td>Once</td>
<td>1 year</td>
</tr>
<tr>
<td></td>
<td>_____ # of Treatments</td>
<td></td>
</tr>
</tbody>
</table>

Nursing Orders

☑ ONC NURSING COMMUNICATION 15
USTEKINUMAB (STELARA):

Hypersensitivity, including anaphylaxis and angioedema, has been reported. Discontinue immediately with signs/symptoms of hypersensitivity reaction and treat appropriately as indicated.

Monitor for signs/symptoms of infection, reversible posterior leukoencephalopathy syndrome (RPLS), and squamous cell skin carcinoma.

☑ ONC NURSING COMMUNICATION 100
May Initiate IV Catheter Patency Adult Protocol

Treatment Parameters

☑ ONC MONITORING AND HOLD PARAMETERS 4
May proceed with treatment if tuberculosis screening test with either TB Screen blood test (QuantiFERON® Gold Plus) or TB skin test have been resulted prior to first dose and the results are negative.

Medications - Induction

☑ Ustekinumab (stelara) 45 Mg Or 90 Mg

☐ ustekinumab (STELARA) 45 MG/0.5ML injection 45 mg

45 mg, Subcutaneous, Once, Starting S, For 1 Doses
Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician

☐ ustekinumab (STELARA) 90 MG/ML injection 90 mg

90 mg, Subcutaneous, Once, Starting S, For 1 Doses
Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician
Medications – Maintenance

<table>
<thead>
<tr>
<th>☑ Ustekinumab (stelara) 45 Mg Or 90 Mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ ustekinumab (STELARA) 45 MG/0.5ML injection 45 mg</td>
</tr>
<tr>
<td>45 mg, Subcutaneous, Once, Starting S, For 1 Doses</td>
</tr>
<tr>
<td>Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>☐ ustekinumab (STELARA) 90 MG/ML injection 90 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>90 mg, Subcutaneous, Once, Starting S, For 1 Doses</td>
</tr>
<tr>
<td>Administer by subcutaneous injection into the top of the thigh, abdomen, upper arms, or buttocks. Rotate sites. Do not inject into tender, bruised, erythematous, or indurated skin. Avoid areas of skin where psoriasis is present. Discard any unused portion. Intended for use under supervision of physician</td>
</tr>
</tbody>
</table>

Telephone order/Verbal order documented and read-back completed. Practitioner's initials ___________